Argos Therapeutics Inc (ARGSQ)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
CEO:
Jeffrey D. Abbey
Employees:
122
4233 TECHNOLOGY DR, DURHAM, NC 27704
9192876300

• *** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

Argos Therapeutics, Inc. is a biopharmaceutical company, which engages in development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its proprietary technology platform called Arcelis. Its product candidates include AGS-003 for the treatment of metastatic renal cell carcinoma, and other cancers; and AGS-004 for the treatment of human immunodeficiency virus. The company was founded by Ralph Steinman on May 8, 1997 and is headquartered in Durham, NC.

Data derived from most recent annual or quarterly report
Market Cap 571.86 Thousand Shares Outstanding10.59 Million Avg 30-day Volume 3.865 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-1.36
Price to Revenue0.3211 Debt to Equity-1.4704 EBITDA-13.864 Million
Price to Book Value0.0 Operating Margin-178.6942 Enterprise Value13.405 Million
Current Ratio0.965 EPS Growth1.062 Quick Ratio0.854
1 Yr BETA 0.7251 52-week High/Low 0.0 / Profit Margin-173.8668
Operating Cash Flow Growth54.4324 Free Cash Flow to Firm (FCFF) TTM -9.339 Million Free Cash Flow to Equity (FCFE) TTM-7.096 Million
Altman Z-Score-53.6083
View SEC Filings from ARGSQ instead.

View recent insider trading info

Argos Therapeutics Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding ARGSQ (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ARGSQ

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2018-04-25 by ABBEY JEFFREY D
  • 4: filed on 2018-04-25 by KATZ RICHARD D
  • 4: filed on 2018-04-25 by HARRELSON LORI R.
  • 4: filed on 2018-04-25 by NICOLETTE CHARLES A.
  • 4: filed on 2018-04-02 by KATZ RICHARD D
  • 4/A: filed on 2018-01-12 by KATZ RICHARD D
  • 4/A: filed on 2018-01-12 by NICOLETTE CHARLES A.
  • 4/A: filed on 2018-01-12 by HARRELSON LORI R.
  • 4/A: filed on 2018-01-12 by ABBEY JEFFREY D
  • 4: filed on 2018-01-12 by HARRELSON LORI R.

    • Events (8k)

  • 8-K: filed on 2018-12-03:
    Item 1.03: Bankruptcy or Receivership
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2018-04-24:
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 8.01: Other Events
  • 8-K: filed on 2018-04-19:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2018-03-07:
    Item 8.01: Other Events
  • 8-K: filed on 2018-02-05:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 3.02: Unregistered Sales of Equity Securities
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K/A: filed on 2018-01-30:
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2018-01-18:
    Item 3.03: Material Modifications to Rights of Security Holders
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2018-01-08:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2017-11-28:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 3.02: Unregistered Sales of Equity Securities
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2017-11-09:
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    KATZ RICHARD D VICE PRESIDENT AND CFO

    • Officer
    		 9,697 2018-04-25 0

    HARRELSON LORI R. VICE PRESIDENT OF FINANCE

    • Officer
    		 11,776 2018-04-25 0

    ABBEY JEFFREY D CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    		 25,450 2018-04-25 0

    NICOLETTE CHARLES A. CSO AND VICE PRESIDENT OF R&D

    • Officer
    		 20,056 2018-04-25 0

    PHARMSTANDARD INTERNATIONAL S.A.

    JOINT STOCK CO PHARMSTANDARD

    • 10% Owner
    		 13,142,784 2017-10-31 0

    MORRISON RICHARD G

    • Director
    		 0 2017-09-26 0

    BIRNER HUBERT

    • Director
    		 0 2017-01-19 0

    ALLEN LEE F MD PHD CHIEF MEDICAL OFFICER

    • Officer
    		 7,378 2017-01-19 0

    VAN DEVENTER SANDER

    • Director
    		 0 2017-01-19 0

    WINTERBOTTOM JOAN CHIEF HUMAN RESOURCES OFFICER

    • Officer
    		 47,248 2017-01-19 0

    CAREY ROBERT

    • Director
    		 0 2017-01-19 0

    KROL IGOR

    • Director
    		 0 2017-01-19 0

    SNYDERMAN RALPH

    • Director
    		 573 2016-12-31 0

    MTIBELISHVILY IRACKLY

    • Director
    		 14,895 2016-12-31 0

    PETROV ANDREI VLADIMIROVICH

    • Director
    		 10,530 2016-09-30 0

    VAN HOLLE PHILIPPE MARIE MARCEL JOSEPH

    • Director
    		 50,955 2016-09-30 0

    FORARGOS B.V.

    • 10% Owner
    		 7,359,051 2016-08-02 0

    VINOGRADOV ALEXEY ALEXANDROVICH

    • Director
    • 10% Owner
    		 3,367 2016-03-31 0

    MIESOWICZ FREDERICK COO

    • Officer
    		 36,843 2016-01-08 0

    LAMARRE JEAN

    • Director
    		 2,500 2015-08-25 0

    UNDERDOWN BRIAN J.

    • Director
    		 0 2015-06-17 0

    PLESSINGER DOUGLAS C. SEE REMARKS

    • Officer
    		 0 2015-06-17 0

    COOPERATIEVE AAC LS U.A.

    FORBION CO-INVESTMENT II COOPERATIEF U.A.

    • 10% Owner
    		 5,848,712 2014-02-12 0

    CAISSE DE DEPOT ET PLACEMENT DU QUEBEC

    • 10% Owner
    		 0 2014-02-06 0

    AURORA VENTURES II LLC

    HARBINGER AURORA QP VENTURE FUND LLC

    HARBINGER AURORA VENTURE FUND LLC

    AV II ARGOS ENRICHMENT, LLC

    • 10% Owner
    		 0 2014-02-06 0

    INTERSOUTH AFFILIATES V LP

    INTERSOUTH PARTNERS IV LP /NC

    INTERSOUTH PARTNERS V, L.P.

    • 10% Owner
    		 0 2014-02-06 0

    TVM V LIFE SCIENCE VENTURES GMBH & CO KG

    TVM V LIFE SCIENCE VENTURES MANAGEMENT GMBH & CO. KG

    FISCHER STEFAN

    GOLL ALEXANDRA

    POLACK AXEL

    • 10% Owner
    		 0 2014-02-06 0

    GRYSKA DAVID W

    • Director
    		 0 2014-02-06 0

    LCC LEGACY HOLDINGS INC.

    LUMIRA CAPITAL I LIMITED PARTNERSHIP

    LUMIRA CAPITAL I QUEBEC LIMITED PARTNERSHIP

    • 10% Owner
    		 0 2014-02-06 0

    KYOWA HAKKO KIRIN CO LTD

    • 10% Owner
    		 70,406 2014-02-06 0

    MIZUHO CAPITAL NO. 3 LIMITED PARTNERSHIP

    • 10% Owner
    		 43,325 2014-02-06 0

    JAIC USSII NO. 1, LLC

    • 10% Owner
    		 0 2014-02-06 0

    MORNINGSIDE VENTURE INVESTMENTS LTD

    • 10% Owner
    		 0 2014-02-06 0

    TFG USA, LLC

    • 10% Owner
    		 36,183 2014-02-06 0

    STRIKER ASIA OPPORTUNITIES FUND CORP

    • 10% Owner
    		 0 2014-02-06 0

    GREEN CROSS CORP.

    • 10% Owner
    		 0 2014-02-06 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    WhaleWisdom Logo

    Elevate your investments